Release date: 2026-01-05 15:02:13 Recommended: 87
Applicable to von Hippel-Lindau (VHL) disease patients requiring treatment for renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgical intervention.